As a professional global BD consultant partner, Angine has advised Jincheng Pharma, a leading integrated pharmaceutical company, on its exclusive licensing agreement with Theramex HQ UK for BIJUVA, a women health care drug in China market for the exclusive commercialization and distribution.
By providing the full services from asset searching, evaluating and business case discussing as well as license agreement negotiating, as Jincheng Pharma’s BD consultant partner, Angine BD team assisted Jincheng Pharma to sign and execute the distribution agreement in May,2025.
BIJUVA (estradiol and progesterone) is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.BIJUVA is a only available, FDA-approved Bio-Identical combination of Estradiol & Micronized Progesterone.
About Angine: Angine is a international business development solution provider company dedicated in the pharma, biotech and medical device fields for the global business partnership building. We are working with our overseas' business partner to introduce the clinical and market unmet projects/products to China by leveraging the local expertise and resources as well as “license-out” the innovative pipeline products from China to overseas partners.
If you have the innovative drug product which would like to explore the China market business opportunities via BD partnership, you can write the email via leoluo@anginebio.com.
